These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

327 related items for PubMed ID: 21530477

  • 1. Studies on the protective efficacy and immunogenicity of Hsp70 and Hsp83 based vaccine formulations in Leishmania donovani infected BALB/c mice.
    Kaur J, Kaur T, Kaur S.
    Acta Trop; 2011 Jul; 119(1):50-6. PubMed ID: 21530477
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Evaluation of the immunoprophylactic potential of a killed vaccine candidate in combination with different adjuvants against murine visceral leishmaniasis.
    Thakur A, Kaur H, Kaur S.
    Parasitol Int; 2015 Feb; 64(1):70-8. PubMed ID: 25316605
    [Abstract] [Full Text] [Related]

  • 4. Induction of cellular and humoral responses by autoclaved and heat-killed antigen of Leishmania donovani in experimental visceral leishmaniasis.
    Nagill R, Mahajan R, Sharma M, Kaur S.
    Parasitol Int; 2009 Dec; 58(4):359-66. PubMed ID: 19638322
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Cocktail of gp63 and Hsp70 induces protection against Leishmania donovani in BALB/c mice.
    Kaur T, Sobti RC, Kaur S.
    Parasite Immunol; 2011 Feb; 33(2):95-103. PubMed ID: 21226722
    [Abstract] [Full Text] [Related]

  • 7. 115 kDa serine protease confers sustained protection to visceral leishmaniasis caused by Leishmania donovani via IFN-γ induced down-regulation of TNF-α mediated MMP-9 activity.
    Choudhury R, Das P, De T, Chakraborti T.
    Immunobiology; 2013 Jan; 218(1):114-26. PubMed ID: 22440312
    [Abstract] [Full Text] [Related]

  • 8. Studies on the protective efficacy of freeze thawed promastigote antigen of Leishmania donovani along with various adjuvants against visceral leishmaniasis infection in mice.
    Thakur A, Kaur H, Kaur S.
    Immunobiology; 2015 Sep; 220(9):1031-8. PubMed ID: 26001730
    [Abstract] [Full Text] [Related]

  • 9. Comparison of liposome based antigen delivery systems for protection against Leishmania donovani.
    Bhowmick S, Mazumdar T, Sinha R, Ali N.
    J Control Release; 2010 Jan 25; 141(2):199-207. PubMed ID: 19818373
    [Abstract] [Full Text] [Related]

  • 10. Leishmania donovani serine protease encapsulated in liposome elicits protective immunity in experimental visceral leishmaniasis.
    Das P, Paik D, Naskar K, Chakraborti T.
    Microbes Infect; 2018 Jan 25; 20(1):37-47. PubMed ID: 28970116
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of the immunogenicity and protective efficacy of killed Leishmania donovani antigen along with different adjuvants against experimental visceral leishmaniasis.
    Thakur A, Kaur H, Kaur S.
    Med Microbiol Immunol; 2015 Aug 25; 204(4):539-50. PubMed ID: 25432859
    [Abstract] [Full Text] [Related]

  • 12. Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis.
    Oliveira-Freitas E, Casas CP, Borja-Cabrera GP, Santos FN, Nico D, Souza LO, Tinoco LW, da Silva BP, Palatnik M, Parente JP, Palatnik-de-Sousa CB.
    Vaccine; 2006 May 01; 24(18):3909-20. PubMed ID: 16556475
    [Abstract] [Full Text] [Related]

  • 13. Vaccination with liposomal leishmanial antigens adjuvanted with monophosphoryl lipid-trehalose dicorynomycolate (MPL-TDM) confers long-term protection against visceral leishmaniasis through a human administrable route.
    Ravindran R, Maji M, Ali N.
    Mol Pharm; 2012 Jan 01; 9(1):59-70. PubMed ID: 22133194
    [Abstract] [Full Text] [Related]

  • 14. A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice.
    Mazumdar T, Anam K, Ali N.
    Vaccine; 2004 Mar 12; 22(9-10):1162-71. PubMed ID: 15003644
    [Abstract] [Full Text] [Related]

  • 15. Studies on the protective efficacy of second-generation vaccine along with standard antileishmanial drug in Leishmania donovani infected BALB/c mice.
    Joshi J, Kaur S.
    Parasitology; 2014 Apr 12; 141(4):554-62. PubMed ID: 24618257
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Vaccination with a novel recombinant Leishmania antigen plus MPL provides partial protection against L. donovani challenge in experimental model of visceral leishmaniasis.
    Bhardwaj S, Vasishta RK, Arora SK.
    Exp Parasitol; 2009 Jan 12; 121(1):29-37. PubMed ID: 18983842
    [Abstract] [Full Text] [Related]

  • 18. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
    Melby PC, Yang J, Zhao W, Perez LE, Cheng J.
    Infect Immun; 2001 Aug 12; 69(8):4719-25. PubMed ID: 11447143
    [Abstract] [Full Text] [Related]

  • 19. Leishmania donovani recombinant iron superoxide dismutase B1 protein in the presence of TLR-based adjuvants induces partial protection of BALB/c mice against Leishmania major infection.
    Daifalla NS, Bayih AG, Gedamu L.
    Exp Parasitol; 2012 Jul 12; 131(3):317-24. PubMed ID: 22580023
    [Abstract] [Full Text] [Related]

  • 20. Th1-stimulatory polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1 kDa offers long-lasting protection against experimental visceral leishmaniasis.
    Kumari S, Samant M, Misra P, Khare P, Sisodia B, Shasany AK, Dube A.
    Vaccine; 2008 Oct 23; 26(45):5700-11. PubMed ID: 18762224
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.